Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash & Equivalents (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Cash & Equivalents for 7 consecutive years, with $45.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 36.16% to $45.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.4 million, a 36.16% decrease, with the full-year FY2025 number at $45.4 million, down 36.16% from a year prior.
  • Cash & Equivalents was $45.4 million for Q4 2025 at Pliant Therapeutics, down from $93.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $114.3 million in Q1 2024 to a low of $25.1 million in Q2 2022.
  • A 5-year average of $63.0 million and a median of $56.3 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 80.28% in 2021, then skyrocketed 215.03% in 2023.
  • Pliant Therapeutics' Cash & Equivalents stood at $51.7 million in 2021, then plummeted by 34.8% to $33.7 million in 2022, then soared by 87.72% to $63.2 million in 2023, then increased by 12.58% to $71.2 million in 2024, then crashed by 36.16% to $45.4 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Cash & Equivalents are $45.4 million (Q4 2025), $93.7 million (Q3 2025), and $86.8 million (Q2 2025).